Tango Therapeutics Inc (TNGX) Stock Price, Quote & News

Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repress...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 320 4900

Website: www.tangotx.com

Address:

201 Brookline Avenue, Suite 901, Boston, United States

justiceforb_85 Jan. 13 at 4:59 AM

$TNGX irrational drop. Great opportunity to add.

0 · Reply

biolover Jan. 9 at 10:35 PM

$TNGX is a beats. Wait till next week. Even if it gets to $3 B. That’s 10% of $RVMD now TNGX addresses 10-15% of all cancers.

2 · Reply

_JAKE Jan. 9 at 7:03 PM

$IMRX Don’t forget $GLUE and $TNGX, they were other diamonds in the ruff. We are on the same track.

0 · Reply

www_larval_com Jan. 8 at 8:52 PM

$SXTC -13%[-27%] $FTEL 7%[-1%] $PAPL -6%[64%] $TNGX -5%[-7%] $SMX -5%[-18%] most notable movement into the final minutes of trading.

0 · Reply

Chauncy_Peppertooth Jan. 8 at 1:02 AM

$TNGX all things considered it’s held up really well. With record high short interest, maybe we see the starting of a squeeze tomorrow with such low volume trades today. It’s going to take a long time to turn 35% of float at 8M shares a day. I’d assume margin calls start happening tomorrow with the price holding so we’ll

0 · Reply

Liatris_spicata Jan. 7 at 11:15 PM

$TNGX Quite a day today- up over 20%, although it backed off some AH. I sold 2/3 of my shares today at $11.20. So while I’ve done well with the stock (so far), with an average price of $8.11 from purchases last year, I cannot say the same for my sister in a clinical trial with one of their drugs. She was removed from the trial this week, as she showed no benefit. Since my decision to invest here was partly a result of her being included, I decided to step back.

1 · Reply

dixiebull Jan. 7 at 8:06 PM

$RVMD got all of it going $LABU $TNGX $VKTX bios

1 · Reply

www_larval_com Jan. 7 at 7:57 PM

Dumbo reporting in! $TNGX just popped 10% higher to 23% (~2Mv) a moment ago, 01/16 options, follow for more volatility.

0 · Reply

TA_Kongen Jan. 7 at 7:54 PM

$RVMD Buyout stuff sending all of these lmfao $ERAS $VSTM $TNGX

2 · Reply

Sixth_Sense Jan. 7 at 6:07 PM

$TNGX looks like she wants to challenge 52 week high 👀

2 · Reply

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Jan 5, 2026, 7:00 AM EST - 8 days ago

Tango Therapeutics Appoints Sung Lee to Board of Directors

Dec 17, 2025, 7:00 AM EST - 27 days ago

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 6 weeks ago

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 21, 2025, 4:20 PM EST - 7 weeks ago

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy

Oct 23, 2025, 5:07 PM EDT - 2 months ago

Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript

Oct 23, 2025, 11:17 AM EDT - 2 months ago

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Oct 23, 2025, 7:20 AM EDT - 2 months ago

Tango Therapeutics Announces $225 Million Financing

Oct 6, 2025, 7:00 AM EDT - 3 months ago

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

Aug 26, 2025, 7:00 AM EDT - 5 months ago

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Jun 27, 2025, 7:00 AM EDT - 7 months ago

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

May 27, 2025, 7:00 AM EDT - 8 months ago

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 8 months ago

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 12, 2025, 7:00 AM EDT - 8 months ago

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 1, 2025, 7:00 AM EDT - 9 months ago

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Mar 25, 2025, 4:30 PM EDT - 10 months ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Feb 27, 2025, 7:00 AM EST - 11 months ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

Jan 30, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Jan 23, 2025, 5:44 AM EST - 1 year ago

Tango Therapeutics: Chance For A Short Squeeze

Dec 3, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 27, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 7:05 AM EST - 1 year ago

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 6, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Sep 10, 2024, 12:45 PM EDT - 1 year ago

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Participate in Upcoming Investor Conferences

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 23, 2024, 9:18 AM EDT - 1 year ago

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

May 23, 2024, 7:19 AM EDT - 1 year ago

Tango Therapeutics to stop development of cancer therapy

May 23, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Announces Discontinuation of TNG348 Program

May 8, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Mar 5, 2024, 4:47 PM EST - 2 years ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

Jan 31, 2024, 7:00 AM EST - 2 years ago

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 25, 2024, 12:46 PM EST - 2 years ago

Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs

Jan 4, 2024, 2:47 AM EST - 2 years ago

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Nov 13, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Nov 8, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Nov 7, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

Oct 23, 2023, 6:26 PM EDT - 2 years ago

Circling Bank On Tango Therapeutics

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

Aug 29, 2023, 5:08 PM EDT - 2 years ago

Tango Therapeutics Announces Updates to Its Board of Directors

Aug 10, 2023, 7:30 AM EDT - 2 years ago

Tango Stock Surges On Peer Data Merits Excitement And Perspective

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces $80 million Private Placement Financing

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Jul 26, 2023, 7:29 PM EDT - 2 years ago

Tango Therapeutics: Partial Phase 1 Data Has Not Helped

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

May 9, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

justiceforb_85 Jan. 13 at 4:59 AM

$TNGX irrational drop. Great opportunity to add.

0 · Reply

biolover Jan. 9 at 10:35 PM

$TNGX is a beats. Wait till next week. Even if it gets to $3 B. That’s 10% of $RVMD now TNGX addresses 10-15% of all cancers.

2 · Reply

_JAKE Jan. 9 at 7:03 PM

$IMRX Don’t forget $GLUE and $TNGX, they were other diamonds in the ruff. We are on the same track.

0 · Reply

www_larval_com Jan. 8 at 8:52 PM

$SXTC -13%[-27%] $FTEL 7%[-1%] $PAPL -6%[64%] $TNGX -5%[-7%] $SMX -5%[-18%] most notable movement into the final minutes of trading.

0 · Reply

Chauncy_Peppertooth Jan. 8 at 1:02 AM

0 · Reply

Liatris_spicata Jan. 7 at 11:15 PM

1 · Reply

dixiebull Jan. 7 at 8:06 PM

$RVMD got all of it going $LABU $TNGX $VKTX bios

1 · Reply

www_larval_com Jan. 7 at 7:57 PM

Dumbo reporting in! $TNGX just popped 10% higher to 23% (~2Mv) a moment ago, 01/16 options, follow for more volatility.

0 · Reply

TA_Kongen Jan. 7 at 7:54 PM

$RVMD Buyout stuff sending all of these lmfao $ERAS $VSTM $TNGX

2 · Reply

Sixth_Sense Jan. 7 at 6:07 PM

$TNGX looks like she wants to challenge 52 week high 👀

2 · Reply

justiceforb_85 Jan. 6 at 4:57 PM

$TNGX awesome movement.

1 · Reply

Merlintrader Dec. 29 at 1:12 PM

$TNGX https://www.merlintrader.com/tngx-tango-therapeutics-inc/

0 · Reply

UgoGreg Dec. 28 at 10:42 PM

$TNGX https://youtu.be/pXFO9_cJJUM

0 · Reply

UncertaintyUniverse Dec. 25 at 5:04 PM

$TNGX The investment case increasingly rests on operational credibility rather than long‑range promises. Cash flow visibility will determine how patient investors remain. Evidence of resilience during turbulence would be constructive. Over time, credibility will hinge on repeatable performance.

0 · Reply

TalkMarkets Dec. 25 at 3:00 PM

3 Stocks With Strong Upside Potential For 2026 Gains $CRC $TNGX $MSFT https://talkmarkets.com/content/stocks--equities/3-stocks-with-strong-upside-potential-for-2026-gains?post=546709&userid=166882

0 · Reply

Tokenist Dec. 25 at 1:45 PM

🔥 3 Stocks With Real Upside Into 2026 👇 🧠 $MSFT – Enterprise AI beast. Copilot + Azure + Office lock-in = recurring AI revenue. Cloud still ripping. ~30% upside. 🧬 $TNGX – High-risk biotech, big reward. Synthetic lethality cancer drugs + early solid data + $225M funding. ~50% upside if trials hit. 🌱 $CRC – Turns California regulation into profit. Carbon capture + tax credits (45Q/LCFS) = sneaky growth energy play. ~45% upside. Different sectors. Same theme: structural tailwinds, asymmetric upside 🚀

1 · Reply

ZacksResearch Dec. 22 at 2:08 PM

Biotech's Big Comeback in 2025: Will These Stocks Maintain Momentum in 2026? 🚀 🔬 $EYPT shares soared 140.5% in 2025 with promising pipeline progress and strong data readouts. 💊 $ANIP's Cortrophin Gel sales jumped 70% in the first nine months of 2025, driving impressive growth. 🧬 $TNGX surged 163.8%, fueled by positive clinical data and strategic pipeline advancements. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2807150/3-biotech-stocks-wall-street-analysts-are-bullish-on-for-2026?cid=sm-stocktwits-2-2807150-body-25740&ADID=SYND_STOCKTWITS_TWEET_2_2807150_BODY_25740

0 · Reply

ZacksResearch Dec. 22 at 1:08 PM

Biotech winners don’t fade — Wall Street’s lining up for 2026 🚀 $EYPT, $ANIP, and $TNGX put up a stellar show in 2025, and analysts are bullish that this momentum can carry into 2026 as well. Strong performance plus continued confidence is a combo investors can’t ignore. See why these three biotech names have analysts bullish heading into 2026 👉 https://www.zacks.com/stock/news/2807150/3-biotech-stocks-wall-street-analysts-are-bullish-on-for-2026?cid=sm-stocktwits-2-2807150-teaser-25738&ADID=SYND_STOCKTWITS_TWEET_2_2807150_TEASER_25738

0 · Reply

UgoGreg Dec. 18 at 10:28 PM

$TNGX https://youtu.be/ygBN8MilTyc

0 · Reply

McKenna14 Dec. 18 at 9:30 PM

$TNGX hmm what is going on ?

0 · Reply

Redbet69 Dec. 18 at 9:29 AM

$TNGX $AVXL $CCCC $CRDF

0 · Reply

JohnTrack Dec. 17 at 12:04 PM

$TNGX update rolling through now... https://www.rapidticker.com/news/tngx-tango-therapeutics-to-participate-in-0c5e70

0 · Reply

Market Cap	1.44B
Revenue (ttm)	42.07M
Net Income (ttm)	-130.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-309.72%
Debt to Equity Ratio	0.00

Volume	2,045,300
Avg Vol	2,927,898
Day's Range	N/A - N/A
Shares Out	134.68M
Stochastic %K	53%
Beta	1.75
Analysts	Strong Sell
Price Target	$13.22